Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sangzhu Yangzheng Yin is a Traditional Chinese Medicine (TCM) herbal formula developed primarily as an adjuvant therapy for gastrointestinal cancers, including colorectal and gastric cancer. The formula is designed to "nourish the upright qi" (Yangzheng) and address the TCM syndrome of "spleen deficiency and dampness-heat," which is commonly observed in patients undergoing chemotherapy. Its primary therapeutic components typically include *Morus alba* (Mulberry leaf/Sang Ye) and *Atractylodes macrocephala* (Bai Zhu), alongside other supportive herbs like *Astragalus* and *Poria*. Research indicates that Sangzhu Yangzheng Yin exerts its effects by modulating the gut microbiota, inhibiting pro-inflammatory signaling pathways such as TLR4/NF-κB, and enhancing systemic immune function. Clinically, it is utilized to improve quality of life, reduce chemotherapy-induced toxicities (such as hand-foot syndrome and gastrointestinal distress), and potentially inhibit tumor progression by altering the tumor microenvironment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sangzhu Yangzheng Yin.